Day One exits Nasdaq: what it means for Day One Biopharmaceuticals stock

Published on 10/01/2026 at 18:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Servier paid USD 21.50 per share on April 23, 2026. Day One Biopharmaceuticals stock joined a USD 2.5 billion transaction after the Nasdaq exit.

DAWN, US23954D1090, Illustration mit AI erstellt.

Day One exits Nasdaq: what it means for Day One Biopharmaceuticals stock is now a question of corporate ownership rather than daily trading. StockTitan reports that Servier completed its cash acquisition of Day One on April 23, 2026, paying USD 21.50 per share and valuing the company at USD 2.5 billion.

Servier takes full ownership

The transaction reached its decisive threshold when 88,180,910 shares, representing 85.34 percent of the shares then outstanding, were validly tendered by the April 22, 2026 expiration. StockTitan says the remaining shares were converted into the same cash consideration, making Day One a wholly owned Servier subsidiary.

The deal also changed the legal and market structure around the former public company. Day One's stock was scheduled for delisting from Nasdaq, its SEC registration was set for termination, and its equity incentive plans and employee stock purchase plan were canceled under the transaction terms, according to StockTitan.

Oncology assets move to Servier

The ownership change transfers Day One's commercial and development portfolio into Servier. The investor-relations page describes Day One as a commercial-stage company advancing medicines for childhood and adult diseases, with a strategy centered on finding, acquiring and developing potential first-in-class or best-in-class programs. Day One Biopharmaceuticals identifies OJEMDA and additional oncology programs as part of that operating model.

The consideration also provides a clear comparison with the former public-market structure: investors received a fixed USD 21.50 cash payment per share, while the total equity value reached USD 2.5 billion. The tender participation rate of 85.34 percent shows that the transaction secured well above the majority threshold required for the follow-on merger.

Day One stock status after the deal

As of October 1, 2026, Day One Biopharmaceuticals stock belongs to a completed acquisition story rather than an active Nasdaq trading story. MarketScreener identifies the security as Day One Biopharmaceuticals, Inc., ticker DAWN, and ISIN US23954D1090, while the transaction record identifies Nasdaq as the former primary listing through the merger documentation. MarketScreener lists the company under DAWN and US23954D1090.